Thank you H.C. Wainwright & Co., LLC for including Voyager in your 5th Annual Neuro Perspectives Virtual Conference, during which Todd Carter, Ph.D., CSO, and Trista Morrison, NACD.DC, CCAO and Chief of Staff to Voyager’s CEO, discussed our advances in delivering neurogenetic medicines and the progress of our wholly owned and partnered programs. The webcast replay can be accessed here: https://lnkd.in/dmcKPgZ2 #investors #biotechnology #innovation
Voyager Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 37,318 followers
Breaking through barriers in gene therapy and neurology
About us
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
- Website
-
http://www.voyagertherapeutics.com
External link for Voyager Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2014
- Specialties
- Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
Locations
-
Primary
Get directions
64 Sidney St
Cambridge, Massachusetts 02139, US
Employees at Voyager Therapeutics, Inc.
Updates
-
We are proud to see BoardProspects feature Nancy Vitale in this month's edition, which recognizes 75 LGBTQ+ board members making a difference. Since 2020, Nancy’s ability to balance high-level strategic thinking with a knack for asking thought-provoking, detailed questions has brought value to Voyager's Board of Directors. We appreciate her passion for prioritizing people and culture, and we’re lucky to have her on our team. #PrideMonth #LGBTQIA #leadership
BoardProspects is proud to share this month's issue of Board Recruitment, our monthly e-publication covering all the latest news and developments in corporate board recruitment. In this issue we celebrate Pride Month by honoring 75 LGBTQ+ board members making a difference. This month’s issue also includes expert analysis from KPMG on midyear trends and priorities for board members as well as guidance from Protiviti on sharpening the board's focus on M&A due diligence. Thank you to Fabrice C Houdart and the association of Association of LGBTQ+ Corporate Directors for partnering with us on this month's issue. Visit https://lnkd.in/e2KS6v4k to access your complimentary copy and register to receive future publications straight to your inbox.
-
-
Thanks to TD Cowen Inc., and Phil Nadeau for hosting Voyager during yesterday's fireside chat as part of the Genetic Medicines & RNA Summit. Hear what Al Sandrock, CEO, and Todd Carter, CSO, shared on the 4 Ps underlying Voyager's progress: robust Pipeline, foundational Platform, key Partnerships, and the Potential of our approach in neurogenetic medicines. The webcast replay can be accessed here: https://bit.ly/4bc8vzK #investors #biotechnology #innovation
-
-
Our CEO, Al Sandrock, MD, PhD, will join biotech industry leaders on a panel at this week’s Longwood Healthcare Leaders event at Massachusetts Institute of Technology. The panel topic, “Identifying Next-Generation Therapeutics," is close to our hearts at Voyager as we work to revolutionize delivery across the blood-brain barrier and enable transformative treatments for neurological diseases. #biotechnology #leadership #drugdevelopment
-
-
Welcome Nathan Jorgensen, PhD, MBA, to the Voyager team as our new Chief Financial Officer. Nate brings a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. His strategic financial insights will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company. Learn more: https://bit.ly/4bXTGls #biotechnology #leadership #drugdevelopment
-
-
At Voyager, we emphasize diversity through year-round events like workshops, trainings, guest speakers, and fundraisers to support the community. Because our focus isn’t just on one particular month, we hadn’t planned to change our logo for PRIDE. But, several employees told us that they appreciate our support of the LGBTQ+ community, that they feel safe to bring their authentic selves to work, and that they think our efforts are worthy of a PRIDE logo. So here it is. Happy PRIDE month, everyone. Learn more: https://lnkd.in/eqyrarfu #teamwork #culture #DEI
-
Over $350K raised for ALS research as part of the Muscular Dystrophy Association's Wings Over Wall Street event! Voyager's own CMO, Toby Ferguson, was honored with a Diamond Award at the event to recognize him as a scientific leader dedicated to the eradication of ALS. Voyager was proud to sponsor the event and support MDA’s work. #EndALS #neurology #researc
Last night we honored Brooke Eby, Fern Cohen, Joann Wright on behalf of the late Victor Wright, Dr. Toby Ferguson, Stephanie Melillo Fradette PharmD, and Scott Sabatino for Price Chopper Supermarkets-Market 32 at Muscular Dystrophy Association’s Wings Over Wall Street. The event grossed over $350,000 for #ALS research. Since 2001, #WingsOverWallStreet led by co-founders Warren Schiffer, LCSW and Larry Schiffer has raised over $13 million to fund research to #EndALS. Join us and donate to hashtag #EndALSwithMDA here: https://lnkd.in/ezgfdfbs We're grateful for the support of the MDA Board of Directors attending including Chairman Governor Brad Henry, Anjan Aralihalli, Christopher Rosa, PhD, Hon. Robert Pipia, Stephen Furnary. Thank you to the MDA Wings Over Wall Street Committee members for making this such a success: Warren J. Schiffer, Co-founder of MDA’s Wings Over Wall Street, with Wings Over Wall Street Committee members Anjan Aralihalli, Jim Condron, Praneetha Desu, Brandon Hanna, Lauren Horak, Danielle Jaycox, Morgan Jaycox, Susan Jaycox, Grace Oakley, Jamie Schiffer, Larry P. Schiffer, Neil Shneider, Kimberly Unger, Lisa Marie Utasi, Jenna Walsh. Thank you to our sponsors CITGO Petroleum Corporation, IEX, Mitsubishi Tanabe Pharma America, Victor R. Wright Foundation, Biogen, Cboe Global Markets, USI Insurance Services, Voyager Therapeutics, Inc., Aegis. Photos by Wenlan Zheng.
-
-
-
-
-
+15
-
-
Thank you, World RNA Series and Huzefa Rupawala, Ph.D., for welcoming Voyager's head of data science, Jeron Chen, to speak at your workshop! It was a great opportunity to bring together bright minds and talk about computational design of AAVs for delivery of RNA.
Hello sunny Boston! 🌞😎 Great to be back to kick off the workshop day proceedings at the very first Computational RNA Design & Delivery Summit! Excellent thought leadership and set of talks from RNA design, data science, bioinformatics and machine learning experts unlocking the next frontiers of computationally-driven RNA therapeutic discovery. A huge thanks to our speakers today covering key topics on RNA predictive structure-function, mRNA/saRNA computational design challenges, AI & LNP screening, Peptide & AAV-based delivery extrahepatic delivery: Mihir Metkar - Moderna Vivek Advani - Seqirus Parminder Mankoo - Liberate Bio Yaoqi Zhou - Shenzen Bay Laboratory Sarah Spencer - Novartis Divita Gilles - DIVINCELL/ Aanastra Inc Jeron Chen - Voyager Therapeutics, Inc. #rna #mrna #sarna #vaccine #computation #AI #datascience
-
-
In honor of amyotrophic lateral sclerosis (ALS) Awareness Month throughout May, Voyager joined the Boston ALS community to raise awareness of this progressive, neurodegenerative disease, and we were pleased to match employee donations in support of The ALS Association efforts. Learn more about the ALS Association and how you can support their mission here to discover, serve, advocate and empower: https://www.als.org/ #ALSAwarenessMonth #EndALS #neurology #research
-
-
Thank you American Society of Gene & Cell Therapy for taking the time to catch up with Voyager Chief Scientific Officer Todd Carter, Ph.D., at #ASGCT2024. We appreciated the opportunity to highlight some of our 12 data presentations and talk about critical advances in delivering medicines across the blood-brain barrier. Tune in to the full episode here: https://bit.ly/3WFkNwV #biotechnology #genetherapy #drugdevelopment
Now on the podcast: Todd Carter, PhD (Voyager Therapeutics, Inc.) talks about changes in the approach to developing #genetherapies for CNS disorders like #HuntingtonsDisease. Listen + subscribe on Apple and Spotify! https://lnkd.in/gZyzGh82